Evidence map›Paper›PMID 40545133›Full record

ArticleJournal of immunological methods2025

Development of an enteric pathogen multiplex immunoassay to measure antibody responses in blood and saliva for integrated serology applications.

Lindsay N Avolio, Nora Pisanic, Kate L Kruczynski, William J Moss, Kawsar R Talaat, Robert W Kaminski, Kristen A Clarkson, Sarah Elwood, Restituta Mosha, Eric R Houpt and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunological methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lindsay N AvolioDepartment of Environmental Health and Engineering, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Nora PisanicDepartment of Environmental Health and Engineering, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Kate L KruczynskiDepartment of Environmental Health and Engineering, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Public Health Microbiology-ARLN, Maryland Department of Health, Baltimore, MD, USA.
William J MossDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Kawsar R TalaatDepartment of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Robert W KaminskiDepartment of Diarrheal Disease Research, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Latham BioPharm Group, Cambridge, MA, USA.
Kristen A ClarksonDepartment of Diarrheal Disease Research, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Horizon Therapeutics, Deerfield, IL, USA.
Sarah ElwoodDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Restituta MoshaHaydom Global Health Research Centre, Haydom, Mbulu, Tanzania.
Eric R HouptDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Estomih R MdumaHaydom Global Health Research Centre, Haydom, Mbulu, Tanzania.
James A Platts-MillsDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Christopher D HeaneyDepartment of Environmental Health and Engineering, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.

Funding

Pilot Project ProgramP30ES032756 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI Marsha Wills-Karp · 2022 to 2026
$6.0M
Arsenic and immune response to influenza vaccination in pregnant women and newbornsR01ES026973 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI HEANEY, CHRISTOPHER D, LABRIQUE, ALAIN BERNARD · 2017 to 2021
$3.6M
Multiplex oral fluid antibody assay for arbovirus diagnosis, surveillance and preventionR21AI139784 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COLLINS, MATTHEW, HEANEY, CHRISTOPHER D · 2018 to 2019
$459k
NIAID NIH HHS R21 AI139784NIEHS NIH HHS P30 ES032756NIEHS NIH HHS R01 ES026973NIOSH CDC HHS K01 OH010193NIOSH CDC HHS T42 OH008428
6 · The paper itself

Abstract

backgroundEnteric infections are a leading cause of global morbidity and mortality, with the highest burden of disease in young children in low- and middle-income countries. Comprehensive profiling of enteric infections, which requires intensive sampling and molecular and culture-based detection methods, may miss recent and historical infections. High-throughput antibody-based testing of blood or non-invasive specimens like saliva can fill this gap, especially in vulnerable populations.

methodsWe developed a bead-based multiplex immunoassay (MIA) that includes enteric pathogen targets from bacteria (Shigella, Enterotoxigenic Escherichia coli [ETEC], Campylobacter, typhoidal Salmonella, non-typhoidal Salmonella); viruses (norovirus, rotavirus, hepatitis E virus, adenovirus, astrovirus); and protozoa (Cryptosporidium, Giardia), as well as select targets for respiratory viruses and vaccine preventable diseases (VPDs). Coupling was optimized for peptide and lipopolysaccharide (LPS) antigens separately and assay performance characterized for both serum and salivary applications.

resultsThe ability to assess IgG and IgA antibody responses in serum ranging over 4 orders of magnitude was demonstrated, allowing for assessment of various phases of infection. The mean inter-operator assay precision was excellent (6.7 % CV in serum IgG and 10.6 % CV in saliva IgG). The MIA was highly correlated (r = 0.72-0.96, p < 0.0001) with reference ELISA antibody titers in selected antigens.

conclusionsImproved scalability of enteric pathogen detection through an MIA may be combined with existing serosurveillance for VPDs and respiratory viruses and complement broad enteric pathogen burden and vaccine studies. This framework for integrated serology provides methods for assessing disease burden to inform prevention and treatment guidelines and guide targeted interventions.

Indexed as

Antibodies, BacterialAntibodies, ProtozoanAntibodies, ViralSalivaSerologic TestsHumansImmunoassayImmunoglobulin AImmunoglobulin GAntibodies, BacterialAntibodies, ProtozoanAntibodies, ViralImmunoglobulin AImmunoglobulin GEnteric infectionsIntegrated serologyLPS antigensMultiplex immunoassaySalivaSerosurveillance

Identifiers

PMID40545133
PMCPMC13163031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.